Potential conflict of interest: Ira M. Jacobson, Schering-Plough consultant, speaker bureau, research support; Merck consultant, GlobeImmune consultant, ...
Impact of Weight-Based Ribavirin with Peginterferon alfa-2b in African Americans with Hepatitis C Virus Genotype 1 Ira M. Jacobson,1 Robert S. Brown Jr,2 Jonathan McCone,3 Martin Black,4 Clive Albert,5 Michael S. Dragutsky,6 Firdous A. Siddiqui,7 Thomas Hargrave,8 Paul Y. Kwo,9 Louis Lambiase,10 Greg W. Galler,11 Victor Araya,12 Bradley Freilich,13 Joann Harvey,14 Louis H. Griffel,14 and Clifford A. Brass,14 for the WIN-R Study Group WIN-R (Weight-based dosing of pegINterferon alfa-2b and Ribavirin) was a multicenter, randomized, open-label, investigator-initiated trial involving 236 community and academic sites in the United States, comparing response to pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in treatment-naive patients with chronic hepatitis C and compensated liver disease. Patients were randomized to receive PEG-IFN alfa-2b at 1.5 g/kg/week plus flat-dose (800 mg/day) or weight-based-dose RBV (800 mg/day for weight 85-105 kg, or 1400 mg/day for >105-
